Axcella is pioneering a new class of products based on the recognition that complicated multifactorial diseases, where numerous cellular networks are involved, require multifunctional treatments. Our answer is Designed Amino Acid Compositions (DAAC™), rationally designed product candidates that are intended to leverage the diversity and synergy of amino acid biology in order to restore health across a network of dysregulated pathways. In addition to their potential to simultaneously address multiple core disease pathologies, we believe our DAAC candidates will have a differentiated tolerability profile in the treatment of patients with complex diseases.
We are committed to a rigorous, data-driven approach without sacrificing speed and efficiency in our development of potentially groundbreaking treatments for patients with unmet needs. Our DAAC candidates are designed, optimized and tested with our Axcellerator™ platform. This innovative paradigm integrates preclinical studies and data from IRB-approved human studies* in a rapid, iterative process to generate candidates with a higher probability of success in less than a year from indication selection. Our Axcellerator platform has already produced a rich pipeline of product candidates in programs that include liver, muscle, CNS and other target indications.
*Studies conducted under food and dietary supplement guidelines
